Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eisai
Eisai
Pharmaceutical Giant Eisai Hit By Ransomware Incident
Infosecurity Magazine
Sun, 06/11/23 - 11:09 pm
Eisai
cyberattack
ransomware
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Eisai
Biogen
Leqembi
Alzheimer's disease
South Korea
Asia
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 06/7/23 - 09:53 pm
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
Tue, 06/6/23 - 10:17 am
FDA
Biogen
Eisai
Alzheimer's disease
Leqembi
PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs
Fierce Pharma
Sun, 06/4/23 - 04:15 pm
Biogen
Eisai
Alzheimer's disease Leqembi
CMS
PhRMA
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Fri, 06/2/23 - 10:18 am
Medicare
Alzheimer's disease
Eisai
Biogen
Leqembi
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Wed, 05/31/23 - 07:02 pm
Alzheimer's disease
patients
clinical trials
Biogen
Eisai
Eli Lilly
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Tue, 05/30/23 - 09:18 pm
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Wed, 05/24/23 - 06:51 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Mon, 05/15/23 - 06:20 pm
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
BioSpace
Tue, 05/9/23 - 11:07 am
Eisai
Bliss Biopharmaceutical
clinical trials
antibody-drug conjugate
Halaven
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Fri, 04/7/23 - 01:58 pm
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Tue, 03/21/23 - 09:58 pm
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
Fri, 03/17/23 - 11:43 am
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Mon, 03/6/23 - 12:11 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
Wed, 03/1/23 - 06:55 pm
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »